10514 Background: RMS mainly affects children and adolescents and is rarely seen in adults. Survival of children with RMS increased dramatically during the last three decades because of the introduction of multiagent chemotherapy in clinical trials (5-yrs overall survival (OS) 73% nonmetastatic vs 24% metastatic disease). By contrast, the scarce data on adult RMS indicate a dismal outcome (reported 5- yrs OS 21–44%). The question is whether this is due to a more advanced stage at diagnosis and/or different histologic subtypes. Methods: Data were collected from RMS pts diagnosed in three Dutch University Medical Centres during 1977–2005. The influence of the prognostic factors on OS were analysed with Cox regression analysis. The estimated survival probabilities were calculated using the Kaplan-Meier with log-rank score. A p-value <0.05 was considered significant. Results: Data from 170 pts were successfully retrieved. Median age at diagnosis was 10 years (range 0–75 yrs). Five-yrs OS in pts <16 yrs was 63.2% versus 34.3% in pts ≥16 yrs (p<0.001). Age as a continuous variable significantly influenced OS in univariate and multivariate analysis (p=0.016 and p= 0.026 resp.). Five-yrs OS in the main histologic groups was highest for nonmetastatic Embryonal RMS (ERMS, 68.2%), followed by nonmetastatic Alveolair RMS (ARMS, 40.0%), and was worst in metastatic disease (11.5%). Unfavorable histologic subtypes were correlated with a higher age; median age ERMS 7.0 years, ARMS 16.0 (correlation coefficients 0.358, p<0.001) In ERMS, metastatic disease at presentation was correlated with higher age (p=0.005). In nonmetastatic ERMS (n=74) univariate and multivariate prognostic factors for OS were age (p=0.002 and p=0.023), IRSG Clinical Group (p=0.030 and p=0.005) and the use of chemotherapy (p<0.001 and p<0.001). Conclusions: Our study indicates that age as a continuous variable is of prognostic significance on survival in all RMS patients as well as in the main subgroup with nonmetastatic ERMS. Increasing age was correlated with advanced stage of disease in ERMS. Whether different biologic behaviour and/or a treatment effects contribute as well is subject of further study. No significant financial relationships to disclose.